In the phase II HERIZON study, CAPOX plus HER-Vaxx improved the outcome compared to CAPOX alone in HER2-positive gastric adenocarcinoma naïve to HER2-targeting therapy [115]. Here, ERBB2 is linked to gastric adenocarcinoma.